J&J scores one-two royalty punch against Genmab in blockbuster Darzalex fight

Notch a win for Johnson & Johnson in its royalty fight with Genmab over the blockbuster multiple myeloma drug Darzalex.

An arbitration tribunal sided with the pharma major Thursday on two issues related to the partners’ license agreement on the superstar med, which also goes by the name daratumumab.